SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Danimer Scientific to Attend the CJS Securities 22nd Annual New Ideas for the New Year Conference

01/11/2022 | 07:03am EDT

Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today that members of Danimer management will participate in the CJS Securities 22nd Annual New Ideas for the New Year Conference to be held virtually on Wednesday, January 12, 2022.

About Danimer Scientific

Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer now holds more than 390 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit www.DanimerScientific.com.

Forward Looking Statements

Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company’s business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company’s manufacturing facilities and suppliers, as well as consumer demand for our products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K/A, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

© Business Wire 2022
05/10TRANSCRIPT : Danimer Scientific, Inc., Q1 2022 Earnings Call, May 10, 2022
05/10Danimer Scientific Announces First Quarter 2022 Results
05/10Earnings Flash (DNMR) DANIMER SCIENTIFIC Reports Q1 Revenue $14.7M, vs. Street Est of $..
05/10DANIMER SCIENTIFIC, INC. : Results of Operations and Financial Condition, Regulation FD Di..
05/10Danimer Scientific, Inc. Provides Earnings Guidance for the Year 2022
05/10Danimer Scientific, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
05/03Kemira and Danimer Scientific expand exclusive partnership to commercialize fully bioba..
05/03Danimer Scientific and Kemira Expand Exclusive Partnership to Commercialize Fully Bioba..
04/26Danimer Scientific Announces Date for First Quarter 2022 Results
More news
Analyst Recommendations on DANIMER SCIENTIFIC, INC.
More recommendations
Financials (USD)
Sales 2022 90,2 M - -
Net income 2022 -104 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,09x
Yield 2022 -
Capitalization 424 M 424 M -
Capi. / Sales 2022 4,70x
Capi. / Sales 2023 2,01x
Nbr of Employees 282
Free-Float 86,9%
Duration : Period :
Danimer Scientific, Inc. Technical Analysis Chart | DNMR | US2362721001 | MarketScreener
Technical analysis trends DANIMER SCIENTIFIC, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,19 $
Average target price 10,00 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Stephen E. Croskrey Chairman & Chief Executive Officer
Michael A. Hajost Chief Financial Officer
Phillip van Trump Chief Science & Technology Officer
Michael Smith Chief Operating Officer
Isao Noda Independent Director
Sector and Competitors